Australia - English SELECT A COUNTRY MEDIA ROOM

MEDIA ROOM

The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

AbbVie Australia follows Medicines Australia’s Code of Conduct and the Therapeutic Goods Act.​ Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing media statements about our prescription medicines. We can issue statements to advise registration of a new medicine, a reimbursement notice of a medicine or news not related to our medicines.


2018


APRIL

Announcement: Venclexta PBS Status

Read full media release here >>


MARCH

AbbVie Kozi Klimbers Raise $16,272 for Rare Cancers!

The Mount Kosciuszko Challenge is an annual event hosted by Rare Cancers Australia to raise awareness and much needed funds for Australians diagnosed with a rare and less common cancer. Joining the challenge for the first year, AbbVie’s Kozi Klimbers jumped at the opportunity to raise money for the cause, and enjoy the 21km climb to the summit on Saturday 17th March. The team of 11 joined 500 other hikers in the great outdoors, and were thrilled not only to reach the top, but to smash their goal of raising over $5000 out of the park. According to Rare Cancers Australia, over 52,000 Australians are diagnosed each year with a rare and less common cancer. The team took that to heart, and helped raise $16,272 that will go directly towards improving awareness, support and treatment of Australians with rare and less common cancers.
 


FEBRUARY

Experts concerned Parksinon’s patients may be missing out on support in the Illawarra

Read full media release here >>


2017


JULY

First Pharmaceutical Benefit Scheme (PBS) listed biologic treatment for Hidradenitis Suppurativa (HS) in Australia

Read full media release here >>


JUNE

AbbVie’s Week of Possibilities

AbbVie Australia’s employees rolled up their sleeves to support their community as part of the company’s global Week of Possibilities program.

The program, in its fourth year, supports employees to work in the community and make a difference for those in need.
In Australia and New Zealand, 132 employees leaned in on 12 projects, providing 660 hours of assistance to activities including preparing the meals for the homeless, maintenance and painting of recreational facilities, sorting donations for Op shops, gardening services and packing hampers for women’s shelters.

Two employees also volunteered 10 days of their time at the Western Desert Dialysis Centre in Alice Springs, where they prepare meals for the clients, and help prepare for the annual Beanie Festival, the major fundraiser for the centre.
 


MAY

AbbVie provides assistance to children in the Philippines

Mercy Ships is a global charity that has operated hospital ships in developing nations since 1978, bringing hope and healing to the forgotten poor by mobilising people and resources worldwide. Each year, Mercy Ships travels the globe providing much needed medical assistance to those unable to access treatment and we are extremely proud and humbled to assist them on their quest. By donating anaesthetic to Operation Hope, the medical crew was able to operate on 35 children to restore cleft lips and palates in the Philippines.
 


2016


JULY

Australian doctor spearheads new arthritis ultrasound method helping patients visualise damage in joints

Read full media statement here >>


JUNE

Children as young as two with juvenile idiopathic arthritis (JIA)1 now have access to new biologic, HUMIRA (adalimumab)

Read full media statement here >>


MAY

Experts call on an estimated 1.9 million people with a partner who may be experiencing sleepless nights to take action

Read full media statement here >>


Leave abbvie.com.au

The AbbVie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The AbbVie Internet site that you have requested may be in a language that differs from your country of origin.

The AbbVie Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this AbbVie site?

Exit abbvie.com.au

The product-specific Internet site that you have requested is intended for the residents of Australia. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The product-specific Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this product-specific site?